Effectiveness of trastuzumab in first-line HER2+ metastatic breast cancer after failure in adjuvant setting: a controlled cohort study.

Effectiveness of trastuzumab in first-line HER2+ metastatic breast cancer after failure in adjuvant setting: a controlled cohort study.

Item
http://www.wikidata.org/entity/Q34641036
Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancerPotential for improvement in cancer management: reducing mortality in the European Union.Patterns of Care and Clinical Outcomes of First-Line Trastuzumab-Based Therapy in HER2-Positive Metastatic Breast Cancer Patients Relapsing After (Neo)Adjuvant Trastuzumab: An Italian Multicenter Retrospective Cohort Study.Trastuzumab re-treatment following adjuvant trastuzumab and the importance of distant disease-free interval: the HERA trial experienceOutcomes of re-treatment with first-line trastuzumab plus a taxane in HER2 positive metastatic breast cancer patients after (neo)adjuvant trastuzumab: A prospective multicenter study.Use and outcomes of targeted therapies in early and metastatic HER2-positive breast cancer in Australia: protocol detailing observations in a whole of population cohort.Trastuzumab and survival of patients with metastatic breast cancer.Commentary The Importance of Cost Estimation for Molecular Epidemiology Studies.Survival outcomes for Australian women receiving trastuzumab for HER2-positive metastatic breast cancer following (neo)adjuvant trastuzumab: a national population-based observational study (2006-2014).The real-world cost-effectiveness of adjuvant trastuzumab in HER-2/neu-positive early breast cancer in Taiwan.First-Line Palliative HER2-Targeted Therapy in HER2-Positive Metastatic Breast Cancer Is Less Effective After Previous Adjuvant Trastuzumab-Based Therapy.Metastatic and triple-negative breast cancer: challenges and treatment options
P2860

Effectiveness of trastuzumab in first-line HER2+ metastatic breast cancer after failure in adjuvant setting: a controlled cohort study.

Item
http://www.wikidata.org/entity/Q34641036
description
2014 nî lūn-bûn
@nan
2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Effectiveness of trastuzumab i ...... ng: a controlled cohort study.
@ast
Effectiveness of trastuzumab i ...... ng: a controlled cohort study.
@en
Effectiveness of trastuzumab i ...... ng: a controlled cohort study.
@nl
type
label
Effectiveness of trastuzumab i ...... ng: a controlled cohort study.
@ast
Effectiveness of trastuzumab i ...... ng: a controlled cohort study.
@en
Effectiveness of trastuzumab i ...... ng: a controlled cohort study.
@nl
prefLabel
Effectiveness of trastuzumab i ...... ng: a controlled cohort study.
@ast
Effectiveness of trastuzumab i ...... ng: a controlled cohort study.
@en
Effectiveness of trastuzumab i ...... ng: a controlled cohort study.
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P478
P50
P577
P698
P932
P356
P1433
P1476
Effectiveness of trastuzumab i ...... ng: a controlled cohort study.
@en
P2093
P2860
P304
P31
P356
10.1634/THEONCOLOGIST.2014-0227
P433
P478
P50
P577
P698
P932